UK Cancer Patients Facing Work Discrimination

According to new research commissioned by Macmillan Cancer Support, cancer patients in the United Kingdom experience discrimination at work on account of their disease.

As many as four in 10 patients returning to work claim to be treated unfairly, which is up by 50 percent over the last three years. As many as one in 10 experienced so much of it that they felt they had no choice but to leave their jobs.

Unfair treatment and discrimination

Examples of such unfair treatment and discrimination include not being granted flexibility of time off in order to make medical appointments; being passed over for promotion opportunities; being given excessive or unfair workloads; and 'feeling abused' by their co-workers.

This mistreatment occurs despite the so-called Equality Act, which should provide employees with protection from this kind of harassment.

Reasonable accommodations not provided

Another one in eight claimed that their employer didn't even bother to carry out any reasonable changes that would have enabled them to continue doing their jobs.

The sample size was small with only 168 adults, but the findings are still alarming. Thirty-seven percent of those who returned to work following cancer treatment responded that they experienced some form of discrimination from either their employer or colleagues or both. Macmillan Cancer Support Chief executive Ciarán Devane commented:

Employers are risking prosecution by flouting their legal responsibility to protect people living with cancer from unfair treatment and stigma at work … As our population grows and ages, and the retirement age rises, cancer will become an increasingly common issue for employees and their managers. It's vital they are equipped to help people with cancer stay in work. It isn't difficult and it is likely to be cheaper and easier than recruiting a replacement or defending a discrimination claim.

Source: Macmillan

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap